Literature DB >> 24345372

Effects of heat-treatment on plasma rich in growth factors-derived autologous eye drop.

E Anitua1, F Muruzabal2, M De la Fuente2, J Merayo-Lloves3, G Orive4.   

Abstract

We have developed and characterized a new type of plasma rich in growth factors (PRGF) derived eye-drop therapy for patients suffering from autoimmune diseases. To determine the concentration of several growth factors, proteins, immunoglobulins and complement activity of the heat-inactivated eye-drop and to study its biological effects on cell proliferation and migration of different ocular surface cells, blood from healthy donors was collected, centrifuged and PRGF was prepared avoiding the buffy coat. The half volume of the obtained plasma supernatant from each donor was heat-inactivated at 56 °C for 1 h (heat-inactivated PRGF). The concentration of several proteins involved on corneal wound healing, immunoglubolins G, M and E and functional integrity of the complement system assayed by CH50 test were determined. The proliferative and migratory potential of inactivated and non-inactivated PRGF eye drops were assayed on corneal epithelial cells (HCE), keratocytes (HK) and conjunctival fibroblasts (HConF). Heat-inactivated PRGF preserves the content of most of the proteins and morphogens involved in its wound healing effects while reduces drastically the content of IgE and complement activity. Heat-inactivated PRGF eye drops increased proliferation and migration potential of ocular surface cells with regard to PRGF showing significant differences on proliferation and migration rate of HCE and HConF respectively. In summary, heat-inactivation of PRGF eye drops completely reduced complement activity and deceased significantly the presence of IgE, maintaining the biological activity of PRGF on ocular surface cells.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  EGF; ELISA; FBS; Fab fragment; Fc fragment; HCE; HConF; HK; IGF-I; IgE; IgG; IgM; Inact-PRGF; PBS; PDGF; PETIA; PRGF; PRP; TGF-β1; VEGF; autoimmune diseases; constant fragment of immunoglogulins; enzyme-linked immunosorbent assay; epithelial growth factor; fetal bovine serum; heat-inactivation; heat-treatment; human conjunctival fibroblasts; human corneal epithelial cells; human keratocytes; immunoglobulin E; immunoglobulin G; immunoglobulin M; inactivated PRGF; insulin-like growth factor I; ocular surface; particle-enhanced turbidimetric immunoassay; phosphate buffered saline; plasma rich in growth factors; platelet-derived growth factor; platelet-rich plasma; transforming growth factor-beta 1; variable fragment of immunoglogulins; vascular endothelial growth factor; wound healing

Mesh:

Substances:

Year:  2013        PMID: 24345372     DOI: 10.1016/j.exer.2013.12.005

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  17 in total

1.  Allogeneic blood-based therapies: hype or hope?

Authors:  E Anitua; M de la Fuente; J Merayo-Lloves; F Muruzabal; G Orive
Journal:  Eye (Lond)       Date:  2016-12-02       Impact factor: 3.775

2.  Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops.

Authors:  Ronald Mauricio Sanchez-Avila; Jesus Merayo-Lloves; Ana Cristina Riestra; Luis Fernandez-Vega Cueto; Eduardo Anitua; Leire Begoña; Francisco Muruzabal; Gorka Orive
Journal:  Int Ophthalmol       Date:  2017-06-15       Impact factor: 2.031

Review 3.  Strategies for reconstructing the limbal stem cell niche.

Authors:  Ghasem Yazdanpanah; Zeeshan Haq; Kai Kang; Sayena Jabbehdari; Mark L Rosenblatt; Ali R Djalilian
Journal:  Ocul Surf       Date:  2019-01-08       Impact factor: 5.033

4.  Human platelet releasates combined with polyglycolic acid scaffold promote chondrocyte differentiation and phenotypic maintenance.

Authors:  Giulia Bernardini; Federico Chellini; Bruno Frediani; Adriano Spreafico; Annalisa Santucci
Journal:  J Biosci       Date:  2015-03       Impact factor: 1.826

5.  Use of Plasma Rich in Growth Factors and ReGeneraTing Agent Matrix for the Treatment of Corneal Diseases.

Authors:  Ronald M Sánchez-Ávila; Edmar Uribe-Badillo; Carlos Fernández-Vega González; Francisco Muruzabal; Borja de la Sen-Corcuera; Begoña Baamonde; Luis M Quirós; Eduardo Anitua; Jesús Merayo-Lloves
Journal:  Vision (Basel)       Date:  2021-07-02

6.  Comparison of the effects of platelet-rich or growth factor-rich plasma on intestinal anastomosis healing in pigs.

Authors:  Gessica Giusto; Cristina Vercelli; Selina Iussich; Massimiliano Tursi; Giovanni Perona; Marco Gandini
Journal:  BMC Vet Res       Date:  2017-06-19       Impact factor: 2.741

7.  Plasma rich in growth factors membrane as coadjuvant treatment in the surgery of ocular surface disorders.

Authors:  Ronald M Sanchez-Avila; Jesús Merayo-Lloves; Ana C Riestra; Silvia Berisa; Carlos Lisa; José Alfonso Sánchez; Francisco Muruzabal; Gorka Orive; Eduardo Anitua
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

8.  Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunctivitis.

Authors:  Borja de la Sen-Corcuera; Jesús Montero-Iruzubieta; Ronald M Sánchez-Ávila; Gorka Orive; Eduardo Anitua; Manuel Caro-Magdaleno; Jesús Merayo-Lloves
Journal:  Clin Ophthalmol       Date:  2020-06-17

Review 9.  Human Serum Eye Drops in Eye Alterations: An Insight and a Critical Analysis.

Authors:  Maria Rosaria De Pascale; Michele Lanza; Linda Sommese; Claudio Napoli
Journal:  J Ophthalmol       Date:  2015-10-04       Impact factor: 1.909

10.  Ex vivo expansion of bovine corneal endothelial cells in xeno-free medium supplemented with platelet releasate.

Authors:  Ming-Li Chou; Thierry Burnouf; Tsung-Jen Wang
Journal:  PLoS One       Date:  2014-06-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.